A Review on Digitalis in Congestive Heart Failure

Tandale A.S, Dr.Rahane R.D, Dhone P.S*, Pawar A.R, Pawade K.S, Lakule S.D.

Matoshri Miratai Aher College Of Pharmacy, Karjule Harya.

*Correspondence: pratikdhone8888@gmail.com

DOI: https://doi.org/10.71431/IJRPAS.2025.4320  

INTRODUCTION

Digitalis glycosides are the oldest drugs used in cardiovascular (CV) therapy, and they are usually provided to patients who have atrial fibrillation (AF), heart failure (HF), or both.1, 2 Twenty-five years ago, digoxin was used by about two-thirds of patients with moderate to severe (systolic) heart failure, while utilization varied widely across Europe, ranging from 85% in Germany to 40% in the UK.3. But since then, digoxin use has drastically declined. In more recent HF trials, its use was either not mentioned at all or reported to be less than 20%.
There are several reasons for this decline, some of which are logical and "scientifically correct," but there are also many misunderstandings and assumptions that might not be as reliable.^2-3

Biological source :-

Digitalis is a biennial or perennial herb that can reach a height of 1.2 meters. The lower basal leaves of the plant are long, hairy, and shaped like an egg, while the upper leaves are nearly completely stalkless and progressively smaller as they climb. It has white or purple blooms and egg-shaped fruits.⁴

Botanical Name: Digitalis purpurea (Linn.)

Family: N.O. Scrophulariaceae

Indian Name: Tilpushpi

Fig : - Digitalis

Constituents :-

Three of the four significant glycosides found in digitalis are cardiac inducers. The most significant are Digitoxin, a highly toxic and cumulative drug that dissolves in water; Digitalin, a liquid that dissolves in water as well; Digitalein, which is unformed but easily soluble in water, making it suitable for subcutaneous administration in pilules as small as a grain; and Digitonin, a cardiac depressant that is identical to Saponin, the primary component of Senega root, and lacks the physiological action specific to Digitalis. Additional components include adipose matter, sugar, brio, slush, changeable oil, and oil.

The amount and character of the active constituents vary according to season and soil 100 About 1.25 percent Digitalin, which is typically present in greater amounts in the wild than in cultivated stores, is produced by a corridor of dried leaves. Not enough research has been done on Digitalis' active ingredients to enable a chemical assay to effectively homogenize for therapeutic action. The different glycosides contained varying from each other in their physiological action, it's impossible to assay the leaves by determining one only of these, analogous as Digitoxin. There is no known method for figuring out Digitalin. As a result, the medication is typically homogenized by a physiological test when the chemical methods of testing fail. One of our oldest apothecary manufacturing companies standardizes the details of this crucial medication by observing how it affects frogs.¹

Patients with and without diabetes :-

Patients with diabetes exhibited more symptoms and signs, were slightly older, were more likely to be female, and had a worse NYHA functional class than those without diabetes (Table 1). Additionally, diabetic patients had higher averages for heart rate, systolic blood pressure, creatinine, and BMI. Compared to people without diabetes, those with diabetes were more likely to have a history of coronary heart disease and hypertension. Compared to patients not on diuretics, diuretic users were more likely to be treated for diabetes.

Daily dose of digoxin :-

Overall, the median daily dose of digoxin was 0.250 mg, with 17.5% of patients taking 0.125 mg, 70.6% taking 0.250 mg, 10.3% using 0.375 mg, and 1.1% taking 0.500 mg. For patients with diabetes, the recommended daily doses of digoxin were 0.125 mg for 17.5%, 0.250 mg for 69.1%, and 0.375 mg for 12.7%. 0.500 mg in 0.8% as well. A patient without diabetes received a daily dose of 0.125 mg of digoxin. 0.250 mg in 20.3%, 0.375 mg in 9.0%, 0.500 mg in 1.1%, and 0.250 mg in 69.5%. People with diabetes and those without had the same average daily dosage (0.250 mg).²⁰

Reasons for the declining role of digoxin in heart failure :-

Digitalis was formerly believed to be a (positive) inotropic drug that inhibited Na/K ATPase, the sodium pump. Since it was believed to be essential to improve the failing heart's pumping ability, positive inotropism was originally believed to have a positive impact on heart failure. Additionally, digoxin had a chronotropic effect that was harmful to the atrioventricular node, which was desirable for HF and AF patients. Because positive inotropism was thought to have favorable effects, digoxin was often administered at the highest permissible dose; in 2001, it was said that the "usual dose of oral digoxin is 0.25–0.375 mg daily.²¹However, the DIG experiment and several other studies later demonstrated that digoxin at lower doses was advantageous and that higher levels (>1.2 ng/mL) were associated with a poorer outcome in HF.²²

A number of post-hoc analyses indicated a negative impact on outcome; however, at first, the majority of these studies were not adjusted for baseline differences, and digoxin was frequently administered to the sickest patients, a phenomenon known as "prescription bias." Digoxin's decrease was caused by these causes as well as the fact that it was once mostly thought to be a positive inotropic medication, which was becoming less and less desirable in the majority of patients with (mild to moderate, chronic) HF.²³

Mechanism Of Action :-

Digoxin's combination inotropic-bradycardic action is unique when compared to all other sympathomimetic inotropes that induce bradycardia.fast heartbeat. Its primary mechanism of action involves the inhibition of sodium pump Na+-K+ ATPase by the intrinsic membrane protein, which promotes calcium absorption via a sodium-calcium exchange system.This outcome is in charge of the drug's inotropic and electrophysiological effects. Digoxin also promotes parasympathetic activation, which results in atrioventricular (AV) nodal inhibition and sinus slowing. Digoxin reduces plasma renin in heart failure patients.activity, blood levels of norepinephrine, and aldosterone, in addition to producing diuresis.⁵

Pharmacokinetics:-

Digoxin has a half-life of 36 to 48 hours and is excreted by the kidneys exponentially when renal function is normal. The elimination half-life in preterm infants may be between 61 and 170 hours. Starting medication with maintenance dosages produced steady-state plateau concentrations after 4 to 5 half-lives (7–10 days) in subjects with normal renal function. Patients with renal insufficiency require lower loading and maintenance dosages of digoxin because their volume of distribution is diminished. A drug called digoxin crosses the placenta and is present in fetal umbilical cord venous blood at levels similar to those found in mother's blood. About 30% of the drug is eliminated by the fecal route and hepatic metabolism.⁶

Preparation:-

The content and efficacy of foxglove drugs vary greatly from one another. Crushed tablets of digitalis leaf are used for administration. The pharmacopoeial tincture, which comes in quantities of 5.15 micrograms, is the most widely used mixture. While the dosage for other infusions is one ounce or more, the infusion is administered in remarkably little volumes of two to four drachms. The tincture contains a decent amount of both the toxin digitalis and digitalin.⁷

Cultivation :-

Few farmers in this nation grow foxglove to make a medication that reliably cures purpurea digitalis. This is something you have to do right now. to possess authentic medicinal seeds for the pharmaceutical industry's supply: Carefully chosen wild seed must be used to cultivate crops. and all of the new variety's variations failed. Although somewhat subdued, loose, well-drained soil, preferably siliceous in origin, is suitable for the growth of the plants. A sunny bank with a timber tree providing shelter yields the best results. According to research, plants that grow in hot, bright environments exhibit considerably more vibrant characteristics than those that are shaded by trees.

Medical Action and uses :-

Digitalis has been used to treat cardiac problems since ancient times. All types of muscle tissue become more active, but the heart and arterioles are most impacted. One of the primary characteristics of the medicine is its impact on movement. The heart and arteries constrict as a result of its absorption, causing blood pressure to rise to an abnormally high level. There was a noticeable slowdown in the heartbeat following a large intake. Moreover, an irregular pulse is regularized with digitalis. A continuous tonic is added to the increased force of heart contraction. Lily-of-the-Valley is always ready to be useful and can be used in place of Digitalis if it doesn't have the desired effect on the heart.

A number of neurological symptoms, such as seeing everything blue and other sensory dislocations, can be brought on by excessive usage of Digitalis. When a person with Digitalis poisoning exhibits a genuinely slow, erratic heartbeat. ⁸

Health benefits of digitalis:-

Simple dilatation arrhythmias, modest ventricular dilatation, pulsations brought on by heart strain, overwork, and cardiac delicacy can all be treated with digitalis. Due to the loss or weakening of inhibitory control and the potential for heart-muscle weariness, it is especially advised for dogfaces with perverse hearts from fighting and dragging marches. Although cactus is a more successful treatment for pulsations that are only nerve-affiliated, it consistently fails to alleviate fierce tachycardia, which is largely a neurological issue. It occasionally corrects the irregular heartbeat, but it does not resolve Grave's complaint. By forcing more blood into the coronaries, the condiment enhances the nutrition of the heart.

When blood circulation is impaired and dropsy occurs, digitalis helps to restore and regulate heart function. By removing obstructions from the feathers and improving blood flow to the feathers, it makes urination easier. Digitalis has been successfully used in a number of ointments and is administered topically to becks and bruises. In situations of burns, it works wonders to save severely injured cells.⁹

Digitalis uses and pharmacology:-

Digitoxin has 1,000 times the energy of the powdered leaves and is quickly and fully absorbed from the digestive system. Digoxin's energy is 300 times more than that of D. purpurea greasepain. One characteristic shared by all cardiac glycosides is their ability to improve cardiac conduction and, consequently, the energy of ventricular contractility. Certain particular will result in arrhythmias and higher lozenge ranges, even when they also contain certain antiarrhythmic parcels. Digitalis inhibits sodium-potassium ATPase in order to work. This increases intracellular calcium by drawing attention to sodium within cells due to an unresisting decrease in the exertion of the sodium-calcium exchanger in the sarcolemma.

The increased intracellular calcium has a beneficial inotropic impact. It is also used to treat reentrant arrhythmias and atrial fibrillation by slowing the ventricular rate because of its vagal action on the parasympathetic nervous system. Digitalis is useless during physical exertion and in situations with high system demands, such as those in actual illness, because it depends on the vagal activity.¹⁰

Drug interaction:-

Digitalis toxin is primarily caused by potassium-depleting diuretics. Calcium may cause severe arrhythmias in digitalized patients, particularly if it is given quickly via the endovenous route. With the potential for digitalis intoxication, quinidine, verapamil, amiodarone, propafenone, NSAID, antimycotic agent, alprazolam, and corticosteroid increase the attention of the liquid body substance Lanoxin by decreasing the amount of the medication's volume of distribution and/or concurrence. Antibacterial medications like erythrocin and clarithromycin (as well as the presumably necessary macrolide antibiotics) may enhance Lanoxin immersion in certain situations. In order for digitalis intoxication to have an impact, a UN agency inactivates Lanoxin through the metabolism of microorganisms in the lower colon. Propantheline and diphenoxylate may increase Lanoxin immersion by decreasing gastrointestinal motility. Enteric Lanoxin immersion may be interfered with by antacids, humus-pectin, sulfasalazine, neomycin, cholestyramine, certain metastatic excrescence drugs, and metoclopramide, which could result in abruptly decreased liquid body substance attention. By adding the non-renal concurrence of Lanoxin, bactericide may decrease the attention of the liquid body substance Lanoxin, especially in situations of urinary organ pathology. Regarding the effects of essential medications (such as quinine and penicillamine) on the attention of liquid bodily substances, there are conflicting data. The requirement for Lanoxin may rise if thyroid medication is given to a digitalized hypothyroid patient. The risk of internal organ arrhythmias will rise with concurrent use of sympathomimetics and Lanoxin. In digitalized cases, muscle relaxants may cause an undetected expulsion of metallic elements from muscle cells, which should result in arrhythmias. Nevertheless, Lanoxin and minuscule number 20 channel blockers may also be helpful in treating chamber fibrillation; their combined effects on Av knot conductivity will result in advanced or total heart block. Beta-blockers and digitalis glycosides both decrease palpitations and slow chamber conductivity.¹⁴

Digitalis toxicity:-

The factory is poisonous in every way. While they are grazing, beasts can become poisoned. Children have historically been disgusted by the smell of the blossoms or by the idea of eating the seeds or parts of the leaves. Deaths have been documented among persons who drank tea made from the factory that was improperly permitted to be comfrey, despite the fact that the bitter taste of digitalis is frequently sufficient to deter input or induce vomiting due to its emetic rates. Ecstasies during treatment are common because digitalis glycosides are slowly eliminated and made up. According to calculations, the frequency of digitalis poisoning ranges from 5 to 23. In severe situations, torpor, bewilderment, storms, and death postdate are signs of factory or meliorated drug poisoning. Other symptoms include contracted pupils, blurred vision, a strong but broken palpitation, nausea, vomiting, dizziness, frequent urination, prostration, muscle weakness, and temblors. Examples of heart symptoms include atrial arrhythmias and atrioventricular block. The effects on the heart are the most harmful. The symptoms of chronic Digitalis poisoning include unheroic green eyesight, gastrointestinal distress, and visual halos. When mild toxicity manifests as atrial fibrillation with a slow ventricular response or intermittent ectopic beats, it is appropriate to temporarily cease the medication and monitor the electrocardiogram. In conjunction with diagnostic procedures such as electrolyte reserves, antiarrhythmics (such lidocaine and phenytoin), atropine, and other medicines that can counteract the cardiovascular effects of glycosides, acute poisonings have been treated with stomach lavage or emesis. Acute ecstasies caused by digitalis and related cardioactive glycosides can be treated with Digibind, an antibody scrap specific to digoxin. This cure is revolutionary for the case of someone who has been gravely poisoned. Digoxin Fab scrap antibodies15 can be used to effectively cancel some factory cardiac glycosides, but not always for Digitalis.¹¹

Trials and guidelines:-

Digoxin has only been the subject of one sizable RCT experiment that looked at outgrowth in HF patients with sinus meters (SR).6. Digoxin, when combined with diuretics and ACE inhibitors, did not lower all-cause mortality in mild to moderate heart failure, which was the main outcome of this 6800-case Digitalis Investigation Group (DIG) experiment that was published in 1997. Digoxin did, however, result in a 28 decrease in hospitalization for worsening heart failure (P<0.001), which was one of the secondary goals. Interestingly, digoxin would have resulted in a statistically significant 15 decrease (hazard rate 0.85; P<0.001) if the primary composite endpoint of CV death and HF hospitalization—which is currently most commonly utilized in HF trials and accepted by the CV community—had been used.7. The 2001 European Society of Cardiology (ESC) HF Guidelines, which were based on DIG, 6 suggested digoxin "to improve the clinical status of patients with persistent HF symptoms despite ACE asset." as well as daily care.8. Digitalis glycosides have gradually lost ground since 2001. According to the most recent 2021 ESC HF Guidelines, digoxin "may be considered in cases with characteristic HF( and SR) with reduced ejection bit EF( HFrEF)" even when medical treatment is at its best (recommendation position IIb-B).9. Digoxin's effects on outgrowth in HF subjects with AF have not yet been investigated in a prospective, placebo-controlled RCT, however. In a recent study, they were contrasted with bisoprolol's effects on life quality. 160 cases of 60 years or older were included in this investigation, which was called the RATE-AF trial (rate control remedy evaluation in unending atrial fibrillation). After six months, quality of life was the main outcome, and there was no difference between the groups. The heart rate decrease was also comparable. However, at 12 months, many secondary endpoints (such as natriuretic peptides, symptoms, and adverse effects) were different and favored low-cure digoxin; for this reason, low-cure digoxin may be viewed as an alternative to beta-blockers in comparable situations. Intriguingly, cardiac glycosides were recommended for all HF cases in the 2001 ESC HF Guidelines, but in 2021, they moved into a class IIb recommendation for cases with sinus meters because the background medication at the time of DIG (only ACE inhibitors and diuretics) was deemed limited in 2021. The recommendation for HF cases with AF was II, which was also influenced by the RATE-AF data. ¹²

Recent developments:-

Interest in digitalis has grown recently once more, and it has been proposed that its implicit component needs to be reexamined because the CV community may have dismissed it too quickly. Digoxin is also likely to be beneficial in HF due to its incredibly low cost. Furthermore, the recent RATE-AF research, which examined the benefits of low-cure digoxin (mean 0.161 mg/day) to bi-soprolol (mean cure 3.2 mg/day) in patients with AF and HF symptoms, produced some interesting results. It's noteworthy that there was no desire for new remedies or increases in pauses on low-cure digoxin, despite the fact that these implicitly beneficial products should be seen as experimental. This supports the idea that low-cure digoxin may be as efficient as sophisticated boluses and possibly safer. ¹³

CONCLUSIONS :-

It is clear that digoxin reverses ouabain's hypertensive impact. Therefore, it appears that the several endogenous cardiotonic steroids work in concert to maintain salt and water balance. Since digoxin and ouabain both inhibit the sodium pump, the previously accepted justification for digoxin therapy is confused. What chemical explanation is there for the contradictory physiological activity of digoxin and ouabain? Are the various cardiac glycosides distributed differently in different tissues, have different affinities for different pump isoforms, or have different signal transduction pathways? Does the pump represent the only cardiac glycoside receptor. ¹⁵

REFERENCE :-

1)      Dr.B.Anil Reddy Maheshwara College of Pharmacy, Department of Pharmaceutical sciences, Hyderabad, Andhra Pradesh, Volume-3

2)      Gheorghiade M, Van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the

management of cardiovascular disorders. Circulation 2006;113:2556–2564. https://doi.

org/10.1161/CIRCULATIONAHA.105.560110

3)      Bavendiek U, Davilla LA, Koch A, Bauersachs J. Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. Eur Heart J 2017;38:2095–2099.

4)      Buckalew, V.M (2005). Endogenous digitalis-like factors. An historical overview. Front Biosci 1,Vol.0:2325-2334.

5)      McGuffin M, Hobbs C, Upton R, Goldberg A,eds (1997). American Herbal Products Association's Botanical Safety Handbook.Boca Raton, FL: CRC Press.

6)      Shumaik GM, Wu AW, Ping AC (1988). Oleander poisoning: treatment with digoxin-specific Fab antibody fragments. Ann Emerg Med. Vol.17:732-735.

7)      Dick M, Curwin J, Tepper D (1991). Digitalis intoxication recognition and management. J Clin Pharmacol .Vol.31:444-447.

8)      Buckalew, V.M (2005). Endogenous digitalis-like factors. An historical overview. Front Biosci 1,Vol.0:2325-2334.

9)      Dec GW (2003). Digoxin remains useful in the management of chronic heart failure. Med Clin North Am .Vol.87:317

10)  Wickersham RM, Novak K (2004), managing eds. Drug Facts and Comparisons. St. Louis, MO: Facts and Comparisons

11)  Johansson S, Lindholm P, Gullbo J, Larsson R, Bohlin L, Cleason P(2001). Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. Anticancer Drugs. Vol. 12:475-483

12)  Kotecha D, Bunting K, Gill SK, Mehta S, Stanbury M, Jones JC, et al. For the RATE-HF team. Effect of digoxin vs. bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life. The RATE-HF randomized clinical trial. JAMA 2020; 324:2497–2508. https://doi.org/10.1001/jama.2020.23138

13)  Van Veldhuisen DJ. Low-dose digoxin in patients with heart failure: less toxic and at least as effective? J Am Coll Cardiol 2002;39:954–956. https://doi.org/10.1016/S0735-1097(02) 01710-2

14)  Litovitz TL, Klein-Schwartz W, White S, Cobaugh DJ, Youniss J, Drab A, et al. 1999 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med., 2000 Sep; 18(5): 517-74.

15)  Mutnick AH. Digoxin. In G. E. Schumacher (Ed.), Therapeutic drug monitoring (469–491). Norwalk: Appleton & Lange, 1995.

16)  Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL,Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees.Effects of candesartan on mortality and morbidity in patients with chronic heartfailure: the CHARM-Overall programme. Lancet 2003; 362: 759-66.

17)  Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.

18)  Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GYH, Steeds RP, Townend J, Kotecha D. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015;351:h4451.

19)  Ather S, Peterson LE, Divakaran VG, Deswal A, Ramasubbu K, Giorgberidze I, Blaustein A, Wehrens XHT, Mann DL, Bozkurt B. Digoxin Treatment in Heart Failure - Unveiling Risk by Cluster analysis of DIG data. Int J Cardiol 2011; 150:264-269.

20)  Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.

21)  Remme WJ, Swedberg K. On behalf of the task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527–1560. https://doi.org/10. 1053/euhj.2001.2783

22)  Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcome in patients with heart failure. JAMA 2003;289: 871–878. https://doi.org/10.1001/jama.289.7.871

23)  Bavendiek U, Davilla LA, Koch A, Bauersachs J. Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. Eur Heart J 2017;38:2095–2099.